title: Phase II trial of carboplatin in soft-tissue sarcoma.
abstract: As part of the Eastern Cooperative Oncology Group program for the assessment of new drugs in sarcomas, a Phase II trial of carboplatin was performed in patients who had received no more than one prior chemotherapy regimen. A total of 50 patients received either 400 mg/m2 or 320 mg/m2 depending on whether they had received prior radiotherapy. A response rate of 16% (95% confidence interval 6-32%) occurred in the 37 patients who had received doxorubicin as their only prior systemic therapy. Three of the six responses were complete and persisted for 7 to 34 months. In contrast none of the 13 patients who received carboplatin after initial progression on doxorubicin and subsequent progression on interferon alpha responded. The overall response rate was therefore 12% (95% confidence interval 5-24%). Toxicity was primarily hematologic, with 14 patients having Eastern Cooperative Oncology Group (ECOG) grade 3 toxicity and no grade 4 or 5 toxicities. In view of the number of complete responses, carboplatin should be studied further in untreated patients with advanced soft tissue sarcoma.
authors.affiliation: University of Wisconsin Clinical Cancer Center, Madison.
authors.forename: D
authors.initials: D
authors.lastname: Goldstein
authors.forename: B
authors.initials: B
authors.lastname: Cheuvart
authors.forename: D L
authors.initials: DL
authors.lastname: Trump
authors.forename: M
authors.initials: M
authors.lastname: Shiraki
authors.forename: R L
authors.initials: RL
authors.lastname: Comis
authors.forename: D C
authors.initials: DC
authors.lastname: Tormey
authors.forename: J E
authors.initials: JE
authors.lastname: Harris
authors.forename: E C
authors.initials: EC
authors.lastname: Borden
mesh_terms: D000328:Adult; D000368:Aged; D016190:Carboplatin / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D014481:United States
chemical_list: D016190:Carboplatin